Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

Fig. 6

Pan-cancer analysis of the immunocorrelation of HLA-DRA. A Correlations between HLA-DRA and 150 immunomodulators (MHC, receptors, chemokines, immunoinhibitors, and immunostimulators) in pan-cancer. The color indicates the correlation coefficient. The asterisks indicate significant differences assessed by Pearson analysis. B Correlations between HLA-DRA and tumor purity in pan-cancer. C Correlations between HLA-DRA and TIICs estimated by TIMER and EPIC algorithms in pan-cancer. The color indicates the correlation coefficient. The asterisks indicate significant differences assessed by Pearson analysis. D Schematic protocol of validation using the pan-cancer TMA cohort. E Representative images revealing HLA-DRA and PD-L1 expression in various tumor types. Magnification, 200×. F Correlation between HLA-DRA and PD-L1 expression in the pan-cancer TMA cohort

Back to article page